Therapeutic impact of human serum albumin-thioredoxin fusion protein on influenza virus-induced lung injury mice

Ryota Tanaka, Yu Ishima, Yuki Enoki, Kazuhiko Kimachi, Tatsuya Shirai, Hiroshi Watanabe, Victor T.G. Chuang, Toru Maruyama, Masaki Otagiri

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Reactive oxygen species (ROS) are the primary pathogenic molecules produced in viral lung infections. We previously reported on the use of a recombinant human serum albumin (HSA)-thioredoxin 1 (Trx) fusion protein (HSA-Trx) for extending the half-life Trx, an endogenous protein with anti-oxidant properties. As a result, it was possible to overcome the unfavorable pharmacokinetic and short pharmacological properties of Trx. We hypothesized that HSA-Trx would attenuate the enhanced ROS production of species such as hydroxyl radicals by neutrophils during an influenza viral infection. The levels of 8-hydroxy-2'-deoxyguanosine and 3-nitrotyrosine were used as indices of the anti-oxidant activity of HSA-Trx. In addition, the cytoprotective effects of HSA-Trx were examined in PR8 (H1N1) influenza virus-induced lung injured mice. The findings show that HSA-Trx reduced the number of total cells, neutrophils, and total protein in BALF of influenza virus-induced lung injured mice. The HSA-Trx treatment significantly decreased the level of 8-hydroxy-2'-deoxyguanosine and 3-nitrotyrosine, but failed to inhibit inducible nitric oxide synthase expression, in the lungs of the virus-infected mice. On the other hand, Tamiflu® treatment also significantly suppressed the production of inflammatory cells and neutrophil infiltration, as well as the protein level in BALF and lung histopathological alterations caused by the influenza virus. The suppressive effect of Tamiflu® was slightly stronger than that of HSA-Trx. Interestingly, Tamiflu® significantly decreased virus proliferation, while HSA-Trx had no effect. These results indicate that HSA-Trx may be of therapeutic value for the treatment of various acute inflammatory disorders such as influenza-virus-induced pneumonia, by inhibiting inflammatory-cell responses and suppressing the overproduction of NO in the lung.

Original languageEnglish
Article number561
JournalFrontiers in Immunology
Volume5
Issue numberNOV
DOIs
Publication statusPublished - 2014 Jan 1
Externally publishedYes

Fingerprint

Thioredoxins
Lung Injury
Orthomyxoviridae
Serum Albumin
Proteins
Oseltamivir
Lung
Therapeutics
Virus Diseases
Oxidants
Reactive Oxygen Species
Neutrophils
Viruses
H1N1 Subtype Influenza A Virus
Neutrophil Infiltration
Nitric Oxide Synthase Type II
Human Activities
Hydroxyl Radical
Human Influenza
Half-Life

Keywords

  • Albumin
  • Anti-oxidization
  • Fusion
  • Influenza virus
  • Thioredoxin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Therapeutic impact of human serum albumin-thioredoxin fusion protein on influenza virus-induced lung injury mice. / Tanaka, Ryota; Ishima, Yu; Enoki, Yuki; Kimachi, Kazuhiko; Shirai, Tatsuya; Watanabe, Hiroshi; Chuang, Victor T.G.; Maruyama, Toru; Otagiri, Masaki.

In: Frontiers in Immunology, Vol. 5, No. NOV, 561, 01.01.2014.

Research output: Contribution to journalArticle

Tanaka, R, Ishima, Y, Enoki, Y, Kimachi, K, Shirai, T, Watanabe, H, Chuang, VTG, Maruyama, T & Otagiri, M 2014, 'Therapeutic impact of human serum albumin-thioredoxin fusion protein on influenza virus-induced lung injury mice', Frontiers in Immunology, vol. 5, no. NOV, 561. https://doi.org/10.3389/fimmu.2014.00561
Tanaka, Ryota ; Ishima, Yu ; Enoki, Yuki ; Kimachi, Kazuhiko ; Shirai, Tatsuya ; Watanabe, Hiroshi ; Chuang, Victor T.G. ; Maruyama, Toru ; Otagiri, Masaki. / Therapeutic impact of human serum albumin-thioredoxin fusion protein on influenza virus-induced lung injury mice. In: Frontiers in Immunology. 2014 ; Vol. 5, No. NOV.
@article{aaac248abd0442eea51a2f9de03258be,
title = "Therapeutic impact of human serum albumin-thioredoxin fusion protein on influenza virus-induced lung injury mice",
abstract = "Reactive oxygen species (ROS) are the primary pathogenic molecules produced in viral lung infections. We previously reported on the use of a recombinant human serum albumin (HSA)-thioredoxin 1 (Trx) fusion protein (HSA-Trx) for extending the half-life Trx, an endogenous protein with anti-oxidant properties. As a result, it was possible to overcome the unfavorable pharmacokinetic and short pharmacological properties of Trx. We hypothesized that HSA-Trx would attenuate the enhanced ROS production of species such as hydroxyl radicals by neutrophils during an influenza viral infection. The levels of 8-hydroxy-2'-deoxyguanosine and 3-nitrotyrosine were used as indices of the anti-oxidant activity of HSA-Trx. In addition, the cytoprotective effects of HSA-Trx were examined in PR8 (H1N1) influenza virus-induced lung injured mice. The findings show that HSA-Trx reduced the number of total cells, neutrophils, and total protein in BALF of influenza virus-induced lung injured mice. The HSA-Trx treatment significantly decreased the level of 8-hydroxy-2'-deoxyguanosine and 3-nitrotyrosine, but failed to inhibit inducible nitric oxide synthase expression, in the lungs of the virus-infected mice. On the other hand, Tamiflu{\circledR} treatment also significantly suppressed the production of inflammatory cells and neutrophil infiltration, as well as the protein level in BALF and lung histopathological alterations caused by the influenza virus. The suppressive effect of Tamiflu{\circledR} was slightly stronger than that of HSA-Trx. Interestingly, Tamiflu{\circledR} significantly decreased virus proliferation, while HSA-Trx had no effect. These results indicate that HSA-Trx may be of therapeutic value for the treatment of various acute inflammatory disorders such as influenza-virus-induced pneumonia, by inhibiting inflammatory-cell responses and suppressing the overproduction of NO in the lung.",
keywords = "Albumin, Anti-oxidization, Fusion, Influenza virus, Thioredoxin",
author = "Ryota Tanaka and Yu Ishima and Yuki Enoki and Kazuhiko Kimachi and Tatsuya Shirai and Hiroshi Watanabe and Chuang, {Victor T.G.} and Toru Maruyama and Masaki Otagiri",
year = "2014",
month = "1",
day = "1",
doi = "10.3389/fimmu.2014.00561",
language = "English",
volume = "5",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "NOV",

}

TY - JOUR

T1 - Therapeutic impact of human serum albumin-thioredoxin fusion protein on influenza virus-induced lung injury mice

AU - Tanaka, Ryota

AU - Ishima, Yu

AU - Enoki, Yuki

AU - Kimachi, Kazuhiko

AU - Shirai, Tatsuya

AU - Watanabe, Hiroshi

AU - Chuang, Victor T.G.

AU - Maruyama, Toru

AU - Otagiri, Masaki

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Reactive oxygen species (ROS) are the primary pathogenic molecules produced in viral lung infections. We previously reported on the use of a recombinant human serum albumin (HSA)-thioredoxin 1 (Trx) fusion protein (HSA-Trx) for extending the half-life Trx, an endogenous protein with anti-oxidant properties. As a result, it was possible to overcome the unfavorable pharmacokinetic and short pharmacological properties of Trx. We hypothesized that HSA-Trx would attenuate the enhanced ROS production of species such as hydroxyl radicals by neutrophils during an influenza viral infection. The levels of 8-hydroxy-2'-deoxyguanosine and 3-nitrotyrosine were used as indices of the anti-oxidant activity of HSA-Trx. In addition, the cytoprotective effects of HSA-Trx were examined in PR8 (H1N1) influenza virus-induced lung injured mice. The findings show that HSA-Trx reduced the number of total cells, neutrophils, and total protein in BALF of influenza virus-induced lung injured mice. The HSA-Trx treatment significantly decreased the level of 8-hydroxy-2'-deoxyguanosine and 3-nitrotyrosine, but failed to inhibit inducible nitric oxide synthase expression, in the lungs of the virus-infected mice. On the other hand, Tamiflu® treatment also significantly suppressed the production of inflammatory cells and neutrophil infiltration, as well as the protein level in BALF and lung histopathological alterations caused by the influenza virus. The suppressive effect of Tamiflu® was slightly stronger than that of HSA-Trx. Interestingly, Tamiflu® significantly decreased virus proliferation, while HSA-Trx had no effect. These results indicate that HSA-Trx may be of therapeutic value for the treatment of various acute inflammatory disorders such as influenza-virus-induced pneumonia, by inhibiting inflammatory-cell responses and suppressing the overproduction of NO in the lung.

AB - Reactive oxygen species (ROS) are the primary pathogenic molecules produced in viral lung infections. We previously reported on the use of a recombinant human serum albumin (HSA)-thioredoxin 1 (Trx) fusion protein (HSA-Trx) for extending the half-life Trx, an endogenous protein with anti-oxidant properties. As a result, it was possible to overcome the unfavorable pharmacokinetic and short pharmacological properties of Trx. We hypothesized that HSA-Trx would attenuate the enhanced ROS production of species such as hydroxyl radicals by neutrophils during an influenza viral infection. The levels of 8-hydroxy-2'-deoxyguanosine and 3-nitrotyrosine were used as indices of the anti-oxidant activity of HSA-Trx. In addition, the cytoprotective effects of HSA-Trx were examined in PR8 (H1N1) influenza virus-induced lung injured mice. The findings show that HSA-Trx reduced the number of total cells, neutrophils, and total protein in BALF of influenza virus-induced lung injured mice. The HSA-Trx treatment significantly decreased the level of 8-hydroxy-2'-deoxyguanosine and 3-nitrotyrosine, but failed to inhibit inducible nitric oxide synthase expression, in the lungs of the virus-infected mice. On the other hand, Tamiflu® treatment also significantly suppressed the production of inflammatory cells and neutrophil infiltration, as well as the protein level in BALF and lung histopathological alterations caused by the influenza virus. The suppressive effect of Tamiflu® was slightly stronger than that of HSA-Trx. Interestingly, Tamiflu® significantly decreased virus proliferation, while HSA-Trx had no effect. These results indicate that HSA-Trx may be of therapeutic value for the treatment of various acute inflammatory disorders such as influenza-virus-induced pneumonia, by inhibiting inflammatory-cell responses and suppressing the overproduction of NO in the lung.

KW - Albumin

KW - Anti-oxidization

KW - Fusion

KW - Influenza virus

KW - Thioredoxin

UR - http://www.scopus.com/inward/record.url?scp=84919462731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919462731&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2014.00561

DO - 10.3389/fimmu.2014.00561

M3 - Article

AN - SCOPUS:84919462731

VL - 5

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - NOV

M1 - 561

ER -